1656-P: TEPLI-REAL: A Real-World Retrospective Study Characterizing Screening and Treatment Patterns for Type 1 Diabetes (T1D) in Individuals Treated with Teplizumab in the U.S.
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1656-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MARWA TUFFAHA und 12 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Teplizumab (TPZ), an anti-CD3 monoclonal antibody, is approved in the US to delay stage 3 T1D onset in individuals aged ≥8 years (y) with stage 2 T1D. We present screening and real-world treatment (Tx) patterns from individuals in the US who received TPZ according to their age group.
Methods
TEPLI-REAL (NCT06892002) was a chart review study including 24 sites in the US. Eligible individuals had ≥1 day of TPZ Tx and were followed until data abstraction.
Results
Median follow-up was 14.6 months (mo). The median age of individuals (n=101) at TPZ initiation was 13.0 y (range 8-62); 75 (74%) were <18 y. For youth, islet autoantibody (IA) testing was most requested by a pediatric endocrinologist (endoc; n=36; 48%) and performed by Autoimmunity Screening for Kids/TrialNet (n=27; 36%) research programs; 74 (99%) had ≥2 IAs (GADA: 73 [97%], IAA: 38 [61%], IA-2A: 49 [78%], and ZnT8A: 56 [85%]). At screening, 67 (90%) had HbA1c tests (median 5.8%; range 4.8-11.5), 36 (49%) had oral glucose tolerance tests (OGTTs), and 7 (9%) had continuous glucose monitoring (CGM) data. The median (range) time between stage 2 confirmation and TPZ initiation was 3.5 (0.6-119.6) mo. TPZ Tx occurred most commonly in hospitals (n=33; 44%), and 71 (95%) completed 14 days of Tx. For adults, IA testing was most requested by an adult endoc (n=9; 35%) and performed at a commercial laboratory (n=10; 38%); 26 (100%) had ≥2 IAs (GADA: 25 [100%], IAA: 7 [33%], IA-2A: 18 [69%], and ZnT8A: 17 [71%]). At screening, 20 (77%) had HbA1c tests (median 6.1%; range 4.7-13.8), 13 (50%) had OGTTs, and none had CGM data. The median (range) time between stage 2 confirmation and TPZ initiation was 6.4 (1.5-184.6) mo in adults. Most TPZ Tx occurred in infusion centers (n=19; 73%), and 23 (88%) completed 14 days of Tx.
Conclusion
This TEPLI-REAL US cohort provides important insights into the care pathway of youth and adults who were treated with TPZ in clinical practice. Disclosure M. Tuffaha: None. J. Felton: Advisory Panel; Ended; Sanofi. Other - Gave educational lectures.; Ended; Sanofi, Med Learning Group, LLC. T.E. Graham: Research Support; Current; Eli Lilly and Company, Novo Nordisk, Abbott Diagnostics, Tandem Diabetes Care, Inc., Sanofi, Novartis Pharmaceuticals Corporation. Advisory Panel; Current; Ascendis Pharma A/S. Research Support; Current; Ascendis Pharma A/S. Advisory Panel; Current; Sanofi. Research Support; Current; Sequel Med Tech. K. Simmons: None. A. Tirosh: Advisory Panel; Current; Medtronic. Research Support; Current; Medtronic. Speaker's Bureau; Ended; Sanofi. Advisory Panel; Ended; Sanofi. Research Support; Current; Sanofi. Speaker's Bureau; Ended; Novo Nordisk A/S, Eli Lilly and Company. Consultant; Current; DreaMed Diabetes, Ltd., Radella Pharma. M. Bonnemaire: Employee; Current; Sanofi. Stock/Shareholder; Current; Sanofi. C.B. Manzano Salgado: Employee; Current; Sanofi. Employee; Ended; IQVIA Inc. T.A. Dex: Stock/Shareholder; Current; Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd. F. Kleinjung: Employee; Current; Sanofi. J.M. Gwinnutt: Employee; Current; IQVIA Inc. F. Negreiro: Employee; Current; IQVIA Inc. J.H. Zaccai: Employee; Current; Sanofi. S.E. Gitelman: Advisory Panel; Current; Sanofi, SAB Biotherapeutics, Inc., Eli Lilly and Company, Genentech, Inc. Research Support; Current; Sanofi, SAB Biotherapeutics, Inc., GentiBio. Other - Member, DSMB; Current; Diamyd. Advisory Panel; Current; AnaptysBio, Inc.
Zitieren
APA
TUFFAHA, M., FELTON, J., GRAHAM, T. E., SIMMONS, K., TIROSH, A., BONNEMAIRE, M., SALGADO, C. B. M., DEX, T. A., KLEINJUNG, F., GWINNUTT, J. M., NEGREIRO, F., ZACCAI, J. H., & GITELMAN, S. E. (2026). 1656-P: TEPLI-REAL: A Real-World Retrospective Study Characterizing Screening and Treatment Patterns for Type 1 Diabetes (T1D) in Individuals Treated with Teplizumab in the U.S. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1656-p
Vancouver
TUFFAHA M, FELTON J, GRAHAM TE, SIMMONS K, TIROSH A, BONNEMAIRE M, et al. 1656-P: TEPLI-REAL: A Real-World Retrospective Study Characterizing Screening and Treatment Patterns for Type 1 Diabetes (T1D) in Individuals Treated with Teplizumab in the U.S. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1656-p
BibTeX
@article{TUFFAHA2026,
author = {TUFFAHA, MARWA and FELTON, JAMIE and GRAHAM, TIMOTHY E. and SIMMONS, KIMBER and TIROSH, AMIR and BONNEMAIRE, MIREILLE and SALGADO, CYNTIA B. MANZANO and DEX, TERRY A. and KLEINJUNG, FRANK and GWINNUTT, JAMES M. and NEGREIRO, FILIPA and ZACCAI, JULIA H. and GITELMAN, STEPHEN E.},
title = {1656-P: TEPLI-REAL: A Real-World Retrospective Study Characterizing Screening and Treatment Patterns for Type 1 Diabetes (T1D) in Individuals Treated with Teplizumab in the U.S},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1656-p}
}
EUVIMED